SCHEMBL25920774

SCHEMBL25920774

CC1Sc2ccc(C(=O)Nc3cccc(S(=O)(=O)Nc4ccc(Cl)cc4)c3)cc2NC1=O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.58
▸ MEN1 O00255 5/20 0.58
▸ LMNA P02545 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ HTT P42858 3/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.58
▸ MAPK1 P28482 2/20 0.58
▸ ALDH1A1 P00352 1/20 0.58
▸ RAB9A P51151 6/20 0.55
▸ NPC1 O15118 5/20 0.55
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ TP53 P04637 1/20 0.52
▸ POLB P06746 2/20 0.50
▸ ATM Q13315 1/20 0.50
▸ TNF P01375 1/20 0.50
▸ NOD1 Q9Y239 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25921444 0.94 KMT2A (0.56) KMT2AMEN1LMNAMAPTHTT
SCHEMBL24125135 0.93 RAB9A (0.61) KMT2AMEN1LMNAMAPTHTT
SCHEMBL25920902 0.92 KMT2A (0.59) KMT2AMEN1LMNAMAPTHTT
SCHEMBL25921447 0.91 KMT2A (0.58) KMT2AMEN1LMNAMAPTHTT
SCHEMBL25921712 0.91 SMN1; SMN2 (0.58) KMT2AMEN1LMNAMAPTHTT
SCHEMBL24124869 0.91 RAB9A (0.57) KMT2AMEN1SMN1; SMN2RAB9ANPC1
SCHEMBL24124708 0.91 RAB9A (0.57) KMT2AMEN1SMN1; SMN2RAB9ANPC1
SCHEMBL25921455 0.90 SMN1; SMN2 (0.56) KMT2AMEN1LMNAMAPTHTT
SCHEMBL25920904 0.89 TP53 (0.62) KMT2AMEN1LMNAMAPTHTT
SCHEMBL25921720 0.89 KMT2A (0.55) KMT2AMEN1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885MEN1 2558/4885LMNA 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback